CD79A and COVID-19: Cross-reactive, naturally-occurring antibodies may confer some degree of protection (174–177);Peripherally depleted in COVID-19 (173, 181) albeit with activated responses (181);Early plasmablast development and antibody response in extrafollicular cells includes IgM, IgG and IgA (173) to N and S proteins (173)DN2 and DN3 cells characterize the EF response with adequate neutralizing capacity (181);Autoantibodies to type I and type III IFNs (e.g.) can be seen in COVID-19 patients (309, 415)